Fernando Holguin, MD, describes the relationship between comorbid metabolic syndrome and pulmonary disease.
From a provider perspective, you need to encourage patients who have asthma and obesity to lose weight, said Fernando Holguin, MD, a pulmonologist and critical care doctor at the University of Colorado Anschutz Medical Campus. Holguin discussed these topics at this year's American Thoracic Society (ATS) meeting.
Transcript
How can understanding metabolic syndrome as a risk factor for pulmonary disease translate into provider/patient pulmonary disease management?
We did a study, not too long ago, using data from the Longitudinal Assessment of Bariatric Surgery study. The study had around 2500 people that underwent bariatric surgery, of which about 550 had asthma. Those patients underwent surgery and lost a significant amount of weight and were followed for up to 5 years. What's interesting is that as weight loss happens, asthma control improves. But when you look at those that, in spite of losing weight, continue to have risk factors for metabolic syndrome, regardless of which one those were, those patients remain at a higher risk of losing control. Somehow they didn't really benefit from the weight loss.
I think from a provider perspective, it is the idea that you need to encourage in patients who have asthma and obesity, weight loss, because certainly weight loss in many patients improves metabolic syndrome profiling. They have to lose at least 5% to 8% of baseline body weight. Then if somebody has metabolic syndrome and asthma, there are potentially some newer treatments that could affect both diseases. For example, let me give you an idea of one: liraglutide. Liraglutide, which is a GLP-1 [glucagon-like peptide-1] agonist to improve insulin sensitivity, it’s been used to treat patients with non–insulin dependent diabetes. That's been shown to, for one, enhance weight loss. But also, there are mechanisms that relate to inflammatory pathways and metabolic pathways, whereas GLP-1 can potentially reduce the frequency of exacerbations in patients with metabolic syndrome and obesity. That's been shown mostly epidemiologically, but there's ongoing clinical trials in that space.
The same can be said about metformin. That works more on the managing glycemic space. That drug has been associated with reduced eosinophil exacerbations in people that take it. Again, more epidemiologically, but there's some phase 2 studies that are ongoing. I think it makes sense from a clinician perspective to treat metabolic syndrome and maybe expect—I don't know for certain—maybe expect that they will have some beneficial ramifications into improving their asthma control or their lung function.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More